Literature DB >> 20036783

A comparison of the frequencies of medical therapies for overactive bladder in men and women: analysis of more than 7.2 million aging patients.

Brian T Helfand1, R Mark Evans, Kevin T McVary.   

Abstract

BACKGROUND: The study of overactive bladder (OAB) symptoms has historically focused on women. However, it is now evident that men, including those with benign prostatic hyperplasia, have OAB symptoms that respond to anticholinergic therapy. The current OAB treatment frequencies by gender are unknown.
OBJECTIVE: The aim of the study was to compare the treatment patterns among men and women diagnosed with OAB. DESIGN, SETTING, AND PARTICIPANTS: Patients ≥45 yr in the IMS Health data set with more than one diagnosis code for OAB during a 12-mo period ending December 2007. INTERVENTION: Treated patients filled a prescription for either an anticholinergic or a tricyclic antidepressant medication; untreated patients did not. MEASUREMENTS: Frequencies of OAB diagnoses and medical therapies by age and gender were compared. RESULTS AND LIMITATIONS: Of the 7,244,501 patients ≥45yr with an OAB diagnosis, 24.4% of these were treated; 75.6% went untreated. Only 25.6% of those treated were men. The diagnosis and treatment frequency increased in both men and women as a function of age. However, in every age group, there was a significantly (p<0.001) decreased proportion of men treated compared with women.
CONCLUSIONS: Despite OAB prevalence, many patients receive no medical treatment. Although the usefulness of OAB medications in men is becoming increasingly recognized, men are significantly less likely to be treated with OAB medications than women.
Copyright © 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20036783     DOI: 10.1016/j.eururo.2009.12.025

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  17 in total

1.  Time-to-effect with darifenacin in overactive bladder: a pooled analysis.

Authors:  Vik Khullar; Jenelle Foote; Yodit Seifu; Mathias Egermark
Journal:  Int Urogynecol J       Date:  2011-10-18       Impact factor: 2.894

Review 2.  Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure?

Authors:  Vik Khullar
Journal:  Int Urogynecol J       Date:  2011-10-20       Impact factor: 2.894

3.  Validation of overactive bladder questionnaire (1-week recall version) in medically complex elderly patients with overactive bladder.

Authors:  Alexandra I Barsdorf; Martin Carlsson; Andrew G Bushmakin; Sheila Quinn; Joseph C Cappelleri; Andreas Pleil
Journal:  Int Urogynecol J       Date:  2017-04-04       Impact factor: 2.894

Review 4.  Urinary incontinence in women.

Authors:  Yoshitaka Aoki; Heidi W Brown; Linda Brubaker; Jean Nicolas Cornu; J Oliver Daly; Rufus Cartwright
Journal:  Nat Rev Dis Primers       Date:  2017-07-06       Impact factor: 52.329

5.  [Conservative treatment in male urinary incontinence].

Authors:  R Kirschner-Hermanns; R Anding
Journal:  Urologe A       Date:  2014-03       Impact factor: 0.639

Review 6.  Global perspective of treatment failures.

Authors:  Sender Herschorn
Journal:  Can Urol Assoc J       Date:  2013-09       Impact factor: 1.862

Review 7.  Overactive bladder in elderly men: epidemiology, evaluation, clinical effects, and management.

Authors:  Tomas L Griebling
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

Review 8.  OnabotulinumtoxinA Treatment for Overactive Bladder in the Elderly: Practical Points and Future Prospects.

Authors:  Hann-Chorng Kuo
Journal:  Drugs Aging       Date:  2016-01       Impact factor: 3.923

9.  Efficacy and tolerability of solifenacin in men with overactive bladder: results of an observational study.

Authors:  Maximilian Burger; Dietmar Betz; Christian Hampel; Monika Vogel
Journal:  World J Urol       Date:  2013-10-18       Impact factor: 4.226

10.  Overactive bladder: the importance of tailoring treatment to the individual patient.

Authors:  Harold P Drutz
Journal:  J Multidiscip Healthc       Date:  2011-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.